Show
Sort by
-
- Journal Article
- A1
- open access
TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer
-
Androgen receptor burden and poor response to abiraterone or enzalutamide in TP53 wild-type metastatic castration-resistant prostate cancer
-
- Journal Article
- A1
- open access
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
-
Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer
-
Extraosseous Ewing's sarcoma, a case report on a rare diagnosis in an 80-year-old woman with a large abdominal mass
-
Prospective non-interventional multicentre observational trial of first-line anti-cancer treatment in patients with metastatic renal cell cancer in Belgium
-
Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing
-
- Journal Article
- A1
- open access
Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas
-
Fulvestrant (Faslodex (TM)) in advanced breast cancer: clinical experience from a Belgian cooperative study
-
Evaluation of EGFR and K-RAS gene status in squamous cell carcinoma of the anal canal.
-
EGFR and K-RAS gene status evaluation in anal canal squamous cell carcinoma
-
Investigation of the EGFR and K-RAS gene status in squamous cell carcinoma of the anal canal
-
Fulvestrant in heavily pretreated patients with advanced breast cancer: a Belgium cooperative study.